RDY Stock Analysis: Buy, Sell, or Hold?
RDY - Dr. Reddy's Laboratories Limited American Depositary Shares
$12.09
0.02 (0.17%)
▲
5d:
+3.07%
30d:
-15.81%
90d:
-9.44%
BUY
HIGH Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Oct 22, 2026
Get Alerted When RDY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RDY trading at deep discount. Market pricing in -4.1% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: RDY trading at deep discount. Market pricing in -4.1% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.99
Based on -2.0% avg growth
INTRINSIC VALUE TODAY
$8.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RDY is currently trading at $12.09, which is considered slightly low relative to its 30-day fair value range of $11.82 to $14.13. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, RDY is in a downtrend. The price is approaching resistance at $12.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.52 (+12.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RDY is in a downtrend. The price is approaching resistance at $12.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.52 (+12.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.82 -
$14.13
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($13.52)
Trading Range Analysis
30-Day Trading Range
$11.82 -
$14.13
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$11.36
Resistance Level
$12.14
Current Trend
Downtrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.23
Wall Street Target
$13.52
(+12.0%)
Revenue Growth (YoY)
-5.6%
Earnings Growth (YoY)
-68.7%
Profit Margin
10.0%
Valuation Discount vs History
-4.1% cheaper
PE vs Historical
0.2 vs 0.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.1%
(market-implied from PE analysis)
1-Year Target
$11.58
(-4%)
2-Year Target
$11.10
(-8%)
3-Year Target
$10.65
(-12%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$13.71
(+14%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: -8.0%)
$836.31
(+6829%)
Base:
(SPY PE: 0.2, Growth: -8.0%)
$9.40
(-22%)
Bear:
(PE: 0.2, Growth: -8.0%)
$7.99
(-34%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Trailing PE: 28.90 | Current EPS (TTM): $0.41
Bull Case
$26.07
(+116%)
Analyst growth 100.0%, PE expands to 31.8
Base Case
$23.70
(+96%)
Market implied 100.0%, PE stable at 28.9
Bear Case
$8.06
(-33%)
Severe decline -20.0%, PE contracts to 24.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.2 to 0.3
Stabilization Target:
$15.55
(+28.8%)
PE Expansion Potential:
+28.8%
Share & Embed Analysis
Last updated: August 04, 2026 2:46 PM ET
Data refreshes hourly during market hours. Next update: 3:46 PM
Data refreshes hourly during market hours. Next update: 3:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 50 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 47 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
